Precigen, Inc. Common Stock (PGEN) Stock
NASDAQ · PGEN
7.78
Fundamentals
Market cap
$2.79B
Price / Earnings ratio
-8.4x
Price / Sales ratio
32.9x
Price / Book ratio
64.7x
Return on assets
-2.7%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Precigen, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees160
CEODr. Helen Sabzevari MPH, Ph.D.
IPO DateSep 25, 2018
HeadquartersGermantown, MD
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Randal J. Kirk J.D. | Executive Chairman | 1953 |
| Dr. Helen Sabzevari MPH, Ph.D. | President, CEO & Director | 1962 |
| Mr. Harry Thomasian Jr. | Chief Financial Officer | 1962 |
| Mr. Rutul R. Shah | Chief Operating Officer | 1981 |
| Mr. Donald P. Lehr J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1975 |
| Mr. Phil Tennant | Chief Commercial Officer | 1970 |
| Mr. Steven M. Harasym | VP & Head of Investor Relations | — |
| Dr. Douglas E. Brough Ph.D. | Senior VP & Head of Research | 1955 |
| Dr. Bryan T. Butman Ph.D. | Senior VP & Head of CMC | 1953 |
| Dr. Amy R. Lankford Ph.D. | Senior VP & Head of Clinical Operations and Regulatory Affairs | — |
Fundamentals
Valuation
Market cap$2.79B
Price-to-sales ratio32.87
Price-to-book value64.66
Price-earnings ratio-8.40
Return on Equity-3317.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.03
Income Statement
Average volume4,409,128
EBITDA$-193.97M
1 year high (52w)$7.95
1 year low (52w)$2.99
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



